24 research outputs found
Targeted Imaging of Urothelium Carcinoma in Human Bladders by an ICG pHLIP Peptide Ex vivo
Bladder cancer is the fifth most common in incidence and one of the most expensive cancers to treat. Early detection greatly improves the chances of survival and bladder preservation. The pH Low Insertion Peptide (pHLIP® peptide) conjugated with a near infrared fluorescent dye (ICG) targets low extracellular pH allowing visualization of malignant lesions in human bladder carcinoma ex vivo. Cystectomy specimens obtained after radical surgery were immediately irrigated with non-buffered saline and instilled with a solution of the ICG pHLIP® construct, incubated, and rinsed. Bladders were subsequently opened and imaged, the fluorescent spots were marked, and a standard pathological analysis was carried out to establish the correlation between ICG pHLIP® imaging and white light pathological assessment. Accurate targeting of bladder lesions was achieved with a sensitivity of 97%. Specificity is 100%, but reduced to 80%, if targeting of necrotic tissue from previous transurethral resections or chemotherapy are considered as false positives. ICG pHLIP® imaging agent marked high grade urothelial carcinomas, both muscle invasive and non-muscle invasive. Carcinoma in situ (CIS) was accurately diagnosed in 11 cases, whereas only 4 cases were seen using white light, so imaging with the ICG pHLIP® peptide offers improved early diagnosis of bladder cancers, and may also enable new treatment alternatives
Novel pH-Sensitive Cyclic Peptides
A series of cyclic peptides containing a number of tryptophan (W) and glutamic acid (E) residues were synthesized and evaluated as pH-sensitive agents for targeting of acidic tissue and pH-dependent cytoplasmic delivery of molecules. Biophysical studies revealed the molecular mechanism of peptides action and localization within the lipid bilayer of the membrane at high and low pHs. The symmetric, c[(WE)4WC], and asymmetric, c[E4W5C], cyclic peptides translocated amanitin, a polar cargo molecule of similar size, across the lipid bilayer and induced cell death in a pH- and concentration-dependent manner. Fluorescently-labelled peptides were evaluated for targeting of acidic 4T1 mammary tumors in mice. The highest tumor to muscle ratio (5.6) was established for asymmetric cyclic peptide, c[E4W5C], at 24 hours after intravenous administration. pH-insensitive cyclic peptide c[R4W5C], where glutamic acid residues (E) were replaced by positively charged arginine residues (R), did not exhibit tumor targeting. We have introduced a novel class of cyclic peptides, which can be utilized as a new pH-sensitive tool in investigation or targeting of acidic tissue
Structure of a Natively-glycosylated HIV-1 Env Reveals a New Mode for VH1-2 Antibody Recognition of the CD4 Binding Site Relevant to Vaccine Design
Background: Structural studies of broadly neutralizing antibodies
(bNAbs) bound to Env trimers have revealed mechanisms by
which bNAbs targeting various epitopes penetrate the glycan
shield to either accommodate or include N-glycans in their
epitopes. Although accessibility to the conserved host receptor
(CD4) binding site (CD4bs) is restricted by surrounding glycans,
VRC01-class bNAbs mimic CD4 binding to share a common mode
of gp120 binding and glycan accommodation using a VH1-2*02-
derived variable heavy (VH) domain. While attractive candidates
for immunogen design, features of VRC01-class bNAbs such
as a high degree of somatic hypermutation (SHM) and a short
(5-residue) light chain (LC) complementarity determining region
3 (CDRL3) (found in only 1% of human LCs) suggest they might
be difficult to elicit through vaccination. However, we recently
isolated a VH1-2*02-derived CD4bs bNAb, named IOMA, that
includes a normal-length (8 residues) CDRL3.
Methods: We used X-ray crystallography to solve the first
structure of a fully- and natively-glycosylated Env trimer in
complex with IOMA, and the V3-loop-directed bNAb 10-1074.
Results: Our structure revealed antibody-vulnerable glycan
holes and roles of complex-type N-glycans on Env that are
relevant to vaccine design, while also demonstrating that IOMA
is a new class of CD4-mimetic bNAb that contains features of
both VH1-2/VRC01-class and VH1-46/8ANC131-class bNAbs.
Conclusions: Analysis of the native glycan shield on HIV-1
Env allows the first full description of the interplay between
heterogeneous untrimmed high-mannose and complex-type
N-glycans within the CD4bs, V3-loop, and other epitopes on Env.
In addition, the structural characterization of IOMA revealed
an alternative pathway from VRC01-class bNAbs relevant to
vaccine design, which could more readily lead to an effective
vaccine response due to higher frequencies of normal-length
CDRL3s compared with the rare 5-residue CDRL3s required for
VRC01-class bNAbs, and a lower need for SHMs
Structure of a Natively-glycosylated HIV-1 Env Reveals a New Mode for VH1-2 Antibody Recognition of the CD4 Binding Site Relevant to Vaccine Design
Background: Structural studies of broadly neutralizing antibodies
(bNAbs) bound to Env trimers have revealed mechanisms by
which bNAbs targeting various epitopes penetrate the glycan
shield to either accommodate or include N-glycans in their
epitopes. Although accessibility to the conserved host receptor
(CD4) binding site (CD4bs) is restricted by surrounding glycans,
VRC01-class bNAbs mimic CD4 binding to share a common mode
of gp120 binding and glycan accommodation using a VH1-2*02-
derived variable heavy (VH) domain. While attractive candidates
for immunogen design, features of VRC01-class bNAbs such
as a high degree of somatic hypermutation (SHM) and a short
(5-residue) light chain (LC) complementarity determining region
3 (CDRL3) (found in only 1% of human LCs) suggest they might
be difficult to elicit through vaccination. However, we recently
isolated a VH1-2*02-derived CD4bs bNAb, named IOMA, that
includes a normal-length (8 residues) CDRL3.
Methods: We used X-ray crystallography to solve the first
structure of a fully- and natively-glycosylated Env trimer in
complex with IOMA, and the V3-loop-directed bNAb 10-1074.
Results: Our structure revealed antibody-vulnerable glycan
holes and roles of complex-type N-glycans on Env that are
relevant to vaccine design, while also demonstrating that IOMA
is a new class of CD4-mimetic bNAb that contains features of
both VH1-2/VRC01-class and VH1-46/8ANC131-class bNAbs.
Conclusions: Analysis of the native glycan shield on HIV-1
Env allows the first full description of the interplay between
heterogeneous untrimmed high-mannose and complex-type
N-glycans within the CD4bs, V3-loop, and other epitopes on Env.
In addition, the structural characterization of IOMA revealed
an alternative pathway from VRC01-class bNAbs relevant to
vaccine design, which could more readily lead to an effective
vaccine response due to higher frequencies of normal-length
CDRL3s compared with the rare 5-residue CDRL3s required for
VRC01-class bNAbs, and a lower need for SHMs
Recommended from our members
Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.
Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans. However, it has not yet been possible to induce adequate serological responses by vaccination. Here, to activate B cells that express precursors of broadly neutralizing antibodies within polyclonal repertoires, we developed an immunogen, RC1, that facilitates the recognition of the variable loop 3 (V3)-glycan patch on the envelope protein of HIV-1. RC1 conceals non-conserved immunodominant regions by the addition of glycans and/or multimerization on virus-like particles. Immunization of mice, rabbits and rhesus macaques with RC1 elicited serological responses that targeted the V3-glycan patch. Antibody cloning and cryo-electron microscopy structures of antibody-envelope complexes confirmed that immunization with RC1 expands clones of B cells that carry the anti-V3-glycan patch antibodies, which resemble precursors of human broadly neutralizing antibodies. Thus, RC1 may be a suitable priming immunogen for sequential vaccination strategies in the context of polyclonal repertoires
Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site
HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env). Variability in high-mannose and complex-type Env glycoforms leads to heterogeneity that usually precludes visualization of the native glycan shield. We present 3.5-Ă…- and 3.9-Ă…-resolution crystal structures of the HIV-1 Env trimer with fully processed and native glycosylation, revealing a glycan shield of high-mannose and complex-type N-glycans, which we used to define complete epitopes of two bNAbs. Env trimer was complexed with 10-1074 (against the V3-loop) and IOMA, a new CD4-binding site (CD4bs) antibody. Although IOMA derives from VH1-2*02, the germline gene of CD4bs-targeting VRC01-class bNAbs, its light chain lacks the short CDRL3 that defines VRC01-class bNAbs. Thus IOMA resembles 8ANC131-class/VH1-46-derived CD4bs bNAbs, which have normal-length CDRL3s. The existence of bNAbs that combine features of VRC01-class and 8ANC131-class antibodies has implications for immunization strategies targeting VRC01-like bNAbs
Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Animal Models With a Polyclonal B Cell Repertoire
Background: Immunization regimens that can elicit broadly
neutralizing antibodies (bNAbs) in humans would be an effective vaccine against HIV-1. Our previous work showed that an immunization strategy involving a sequence of Env-based germline targeting immunogens that were gradually engineered to resemble the native Env protein, successfully elicited bNAb-like antibodies in a knock-in mouse carrying the inferred germline PGT121/10-1074 antibody. Despite this achievement, immunization protocols that elicit bNAbs in systems with a polyclonal B cell repertoire have not been reported to date. The low frequencies of germline bNAb precursors in polyclonal systems hinder their activation by immunization which therefore requires high affinity immunogens. In addition, competition between different epitope-specific B cells in polyclonal germinal centers may frustrate bNAb development.
Methods: Based on our previous results in knock-in mice, we have aimed to optimize sequential immunization strategies to elicit bNAbs in animal models with polyclonal B cell repertoires.
Results: The results of immunization experiments in several animal models will be presented
Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Animal Models With a Polyclonal B Cell Repertoire
Background: Immunization regimens that can elicit broadly
neutralizing antibodies (bNAbs) in humans would be an effective vaccine against HIV-1. Our previous work showed that an immunization strategy involving a sequence of Env-based germline targeting immunogens that were gradually engineered to resemble the native Env protein, successfully elicited bNAb-like antibodies in a knock-in mouse carrying the inferred germline PGT121/10-1074 antibody. Despite this achievement, immunization protocols that elicit bNAbs in systems with a polyclonal B cell repertoire have not been reported to date. The low frequencies of germline bNAb precursors in polyclonal systems hinder their activation by immunization which therefore requires high affinity immunogens. In addition, competition between different epitope-specific B cells in polyclonal germinal centers may frustrate bNAb development.
Methods: Based on our previous results in knock-in mice, we have aimed to optimize sequential immunization strategies to elicit bNAbs in animal models with polyclonal B cell repertoires.
Results: The results of immunization experiments in several animal models will be presented
Comparative Study of Tumor Targeting and Biodistribution of pH (Low) Insertion Peptides (pHLIP® Peptides) Conjugated with Different Fluorescent Dyes
Purpose
Acidification of extracellular space promotes tumor development, progression, and invasiveness. pH (low) insertion peptides (pHLIP® peptides) belong to the class of pH-sensitive membrane peptides, which target acidic tumors and deliver imaging and/or therapeutic agents to cancer cells within tumors. Procedures
Ex vivo fluorescent imaging of tissue and organs collected at various time points after administration of different pHLIP® variants conjugated with fluorescent dyes of various polarity was performed. Methods of multivariate statistical analyses were employed to establish classification between fluorescently labeled pHLIP® variants in multidimensional space of spectral parameters.
Results
The fluorescently labeled pHLIP® variants were classified based on their biodistribution profile and ability of targeting of primary tumors. Also, submillimeter-sized metastatic lesions in lungs were identified by ex vivo imaging after intravenous administration of fluorescent pHLIP® peptide.
Conclusions
Different cargo molecules conjugated with pHLIP® peptides can alter biodistribution and tumor targeting. The obtained knowledge is essential for the design of novel pHLIP®-based diagnostic and therapeutic agents targeting primary tumors and metastatic lesions
The microanatomic segregation of selection by apoptosis in the germinal center
B cells undergo rapid cell division and affinity maturation in anatomically distinct sites in lymphoid organs called germinal centers (GCs). Homeostasis is maintained in part by B cell apoptosis. However, the precise contribution of apoptosis to GC biology and selection is not well defined. We developed apoptosis-indicator mice and used them to visualize, purify, and characterize dying GC B cells. Apoptosis is prevalent in the GC, with up to half of all GC B cells dying every 6 hours. Moreover, programmed cell death is differentially regulated in the light zone and the dark zone: Light-zone B cells die by default if they are not positively selected, whereas dark-zone cells die when their antigen receptors are damaged by activation-induced cytidine deaminas